Skyrizi and Prostatic specific antigen increased - a phase IV clinical study of FDA data

Summary:

Prostatic specific antigen increased is reported as a side effect among people who take Skyrizi (risankizumab-rzaa), especially for people who are 60+ old, have been taking the drug for 1 - 2 years also take Humira, and have Psoriasis.

The phase IV clinical study analyzes which people have Prostatic specific antigen increased when taking Skyrizi. It is created by eHealthMe based on reports of 45,344 people who have side effects when taking Skyrizi from the FDA, and is updated regularly.

What is Skyrizi?

Skyrizi has active ingredients of risankizumab-rzaa. eHealthMe is studying from 45,385 Skyrizi users. Check the latest studies of Skyrizi.

What is Prostatic specific antigen increased?

Prostatic specific antigen increased is found to be associated with 717 drugs and 692 conditions by eHealthMe. Check the latest studies of Prostatic specific antigen increased.

On Aug, 07, 2026

45,344 people reported to have side effects when taking Skyrizi.
Among them, 34 people (0.07%) have Prostatic specific antigen increased.

Could Skyrizi cause Prostatic specific antigen increased?

Among these 34 people:

How long have people been on Skyrizi when they have Prostatic specific antigen increased? *

What is the age of people who have Prostatic specific antigen increased when taking Skyrizi? *

What are other drugs people take besides Skyrizi? *

What are other side effects people have besides Prostatic specific antigen increased? *

Prostate Cancer: 19 people, 55.88%
Urinary Retention Postoperative: 4 people, 11.76%
Seminal Vesicular Disorder (disease of seminal vesicles): 4 people, 11.76%
Bundle Branch Block Right (absence of transmission of electric impulses from the atrioventricular (av) bundle of his to the right ventricle): 3 people, 8.82%
Enlarged Heart: 3 people, 8.82%
Aortic Arteriosclerosis (hardening of the aortic arteries): 3 people, 8.82%
Aortic Elongation: 3 people, 8.82%
Stasis Dermatitis (skin inflammation caused by blood pooling in the veins in your legs): 3 people, 8.82%
Drug Ineffective: 3 people, 8.82%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 3 people, 8.82%

What are the existing conditions these people have? *

Psoriasis (immune-mediated disease that affects the skin): 29 people, 85.29%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 4 people, 11.76%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 5.88%
Prostatic Disorder: 1 person, 2.94%
Diabetes: 1 person, 2.94%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 2.94%

* Approximation only. Some reports may have incomplete information.

Do you take Skyrizi and have Prostatic specific antigen increased?

- Check whether Prostatic specific antigen increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Skyrizi:

Skyrizi (45,385 reports)

Browse all side effects of Skyrizi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Prostatic specific antigen increased:

Prostatic specific antigen increased (717 drugs)

Browse all the conditions that are associated with Prostatic specific antigen increased:

Prostatic specific antigen increased (692 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on risankizumab-rzaa (the active ingredients of Skyrizi) and Skyrizi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.